Researchers found that pralsetinib achieved an overall response rate of 70% and complete response rate of 11% in patients with no prior systemic treatment for advanced RET fusion-positive NSCLC. In the thyroid arm, the ORR was 71% in patients with treatment-naïve RET-mutant medullary thyroid cancer.
The Phase II study showed that sotorasib achieved a 37.1% objective response rate and 12.5 months median overall survival in previously treated patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC). The drug was found to be safe and tolerable, with manageable toxicities.
Researchers discovered MCAD's protective role in glioblastoma cells, which relies on the enzyme to detoxify toxic byproducts of fatty acid metabolism. Inhibiting MCAD appears to be specific and potent in killing glioblastoma cells.
Researchers developed an AI-based tool called SCMER to identify rare groups of biologically important cells from single-cell datasets. The tool was applied to analyze several published datasets, revealing new genes and proteins involved in tumor development and drug resistance.
A combination of ponatinib and blinatumomab achieves 100% complete response rate and 85% complete molecular remission in newly diagnosed patients, reducing the risk of treatment-related complications. The treatment is safe and well-tolerated, with no additional toxicity observed when used together.
In a Phase I trial, IACS-6274 demonstrated successful target inhibition and early signs of anti-tumor activity in 60% of evaluable patients. Durable disease stabilization was observed in six patients with biomarker-defined advanced cancers.
A new preclinical study from the University of Texas MD Anderson Cancer Center found that cord blood-derived NK cells combined with AFM13 displayed potent anti-tumor activity against CD30+ lymphoma cells. The therapy showed improved tumor control and survival in animal models with minimal side effects.
Researchers at the University of Texas M.D. Anderson Cancer Center have discovered that targeting the mitochondrial enzyme DHODH can induce ferroptosis and suppress tumor growth in cancer cells. The study suggests a new therapeutic strategy for inducing ferroptosis, which could have broad implications for treating various types of cancer.
Researchers created a spatial atlas of early-stage lung cancer and normal lung tissue at single-cell resolution, providing insights into tumor development and immune cell interactions. The study identified CD24 as a new immunotherapy target for lung cancer treatment, correlating with poor clinical outcomes and shortened survival.
A Phase II trial found that BKV-specific T cells from healthy donors are safe and effective in treating debilitating complications after stem cell transplants. Patients experienced rapid responses, with 81.6% showing improvement after 28 days, and no cases of severe GVHD or toxicities.
Researchers at the University of Texas MD Anderson Cancer Center have identified a new surface protein, MT1-MMP, as a promising therapeutic target for osteosarcoma. The protein is highly expressed on the surface of osteosarcoma cells but not in normal human tissues, making it an attractive target for antibody-drug conjugate therapy.
Researchers from MD Anderson Cancer Center present promising results on RET fusion-positive cancers, HGG, LGG, and ovarian cancer. The FDA-approved selpercatinib shows clinical benefits in preventing or inhibiting tumor growth beyond lung and thyroid cancers.
Mutant KRAS and p53, the most frequently mutated genes in pancreatic cancer, work together through CREB1 to drive tumor growth and metastasis. Blocking CREB1 reversed these effects and reduced metastases, suggesting a promising new therapeutic target for this deadly cancer.
A novel method for single-cell DNA sequencing has enabled faster and deeper study of chromosome evolution in triple-negative breast cancers. The technique revealed that these cancers undergo continued genetic copy number changes after an initial burst of chromosomal instability, which may explain why treatments are not always effective.
A new study found that a high rate of genetic mutations within a tumor (high tumor mutation burden) can predict clinical responses to immune checkpoint inhibitors in certain cancer types, such as melanoma, lung and bladder cancer. However, this was not the case for other cancers, including breast, prostate and brain cancers.
Researchers at the University of Texas MD Anderson Cancer Center discovered that collagen produced by cancer-associated fibroblasts slows tumor progression in pancreatic cancer. Collagen helps block immune signals that lead to suppression of anti-tumor immune response.
The NEOSTAR trial found that combination therapy produced significant clinical benefits, including higher major pathologic response rates and enhanced tumor immune cell infiltration. The treatment also triggered immunological memory, which may translate to a reduced risk of tumor relapse.
Researchers have developed a comprehensive framework to classify small-cell lung cancer into four unique subtypes based on gene expression. The study identifies potential therapeutic targets for each type, including an inflamed group that tends to be more responsive to immunotherapy.
Researchers developed CopyKAT, a new computational technique that accurately differentiates between cancer and normal cells in solid tumor samples. The tool uses gene expression data to identify aneuploidy and distinct subpopulations within cancer cells.
A new study found that a Mediterranean-style diet may help slow the progression of prostate cancer in men who are not seeking immediate treatment. Men with localized prostate cancer who followed a more plant-based diet had a lower risk of cancer growth or advancement, regardless of their age, PSA levels, or tumor volume.
Researchers at University of Texas M. D. Anderson Cancer Center discovered NIK protein essential for T cell metabolic shift during activation, regulating anti-tumor immunity. Elevated NIK activity in T cells may improve adoptive therapy efficacy.
Researchers developed a gene expression signature that robustly predicts patient survival in patients with peritoneal carcinomatosis, a form of metastatic gastric cancer. The signature is associated with tumor cell populations and lineage compositions, offering potential for tailored treatment strategies.
The study showed that the combination of chemotherapy and blinatumomab resulted in increased survival rates and achieved a high rate of MRD negativity for patients with Ph-negative B-cell ALL. This treatment approach has the potential to improve long-term outcomes for these patients.
A novel targeted therapy, POMHEX, has been developed to block metabolic pathways in brain cancer cells with specific genetic defects. The study found that the small-molecule enolase inhibitor effectively killed brain cancer cells missing ENO1, and showed promise in animal models of this type of cancer.
Researchers from MD Anderson Cancer Center present promising clinical data on combination therapies for patients with metastatic melanoma and advanced refractory solid tumors. The treatments showed activity in activating immune pathways, leading to antitumor responses.
The study generated a valuable resource to aid in predicting drug sensitivity, understanding therapeutic resistance mechanisms, and identifying optimal combination treatment strategies. The dataset includes expression changes in over 200 clinically relevant proteins across more than 300 cell lines after treatment with 168 different com...
A Phase I trial found neoadjuvant combination immunotherapy with tremelimumab and durvalumab showed early signs of activity in patients with high-risk disease, with a pathologic complete response rate of 37.5%.
Researchers discovered that cancer mutations follow specific patterns, with internal factors leading to enriched mutations in active domains and external factors resulting in mutations in inactive domains. This understanding may lead to new therapeutic targets and treatment options.
A study at MD Anderson Cancer Center found that monitoring early changes in circulating tumor DNA can predict patient outcomes. Infused CAR T cells with certain characteristics are associated with better treatment responses, while those with exhaustion signatures may experience poor outcomes.
A new bioinformatics tool called DrBioRight has been developed to enable biomedical researchers to conduct routine analyses of large datasets without specialized expertise in bioinformatics or programming languages. The tool uses a natural-language interface to allow users to ask questions and receive intuitive analysis results.
In a Phase I clinical trial, sotorasib achieved a confirmed response rate of 32.2% and disease control rate of 88.1% in patients with KRAS G12C-mutant non-small cell lung cancer, with durable clinical benefits and manageable toxicities
A preclinical study from MD Anderson and BridgeBio's Navire Pharma shows that SHP2 inhibition can overcome osimertinib resistance in lung cancer. The study found that IACS-13909 suppressed tumor cell proliferation and caused tumor regression in various activated kinase-driven models.
A Phase II trial found that a combination of ipilimumab and nivolumab generated durable responses in 25% of patients with metastatic castration-resistant prostate cancer. The treatment achieved disease control in 46.9% of patients, with median progression-free survival of 5.5 months.
The Phase I/II LIBRETTO-001 trial found that selpercatinib achieved durable objective responses in the majority of participants with RET gene fusions, including an ORR of 85% in previously untreated patients. The study also showed promising results in patients with brain metastases and thyroid cancers.
A Phase II trial conducted at the University of Texas M. D. Anderson Cancer Center found a 51% overall response rate in patients with BRAF-mutated cholangiocarcinoma treated with dabrafenib plus trametinib, providing a much-needed treatment option for patients with treatment-resistant advanced disease.
Researchers at MD Anderson Cancer Center found that some commercially available serological tests only detect N-protein antibodies, which may not indicate immunity to reinfection. S-RBD antibody detection is considered a better indicator of protection against COVID-19 reinfection.
A Phase III trial led by the University of Texas MD Anderson Cancer Center found that combining venetoclax and azacitidine improved overall survival and achieved a 66.4% complete remission rate in patients with acute myeloid leukemia.
The study found that social distancing policies implemented in the US and globally led to significant reductions in SARS-CoV-2 transmission, with an estimated 1.57 million cases prevented over a two-week period. The researchers also observed a strong correlation between decreased mobility and reduced virus transmission.
A recent study by the University of Texas M. D. Anderson Cancer Center found that greater inactivity is independently associated with a higher risk of dying from cancer. Replacing sedentary time with physical activity, such as 30 minutes of cycling or walking, can lower this risk.
Researchers discovered a novel combination of biomarkers from baseline tumor tissues that predict improved clinical responses and prolonged survival in patients with advanced bladder cancer. ARID1A mutations and CXCL13 expression were associated with better overall survival, suggesting potential patient selection improvements.
A Phase II clinical trial has demonstrated a 46.5% objective response rate to tepotinib in patients with advanced non-small cell lung cancer and the MET exon 14 skipping mutation. The study's findings provide a new treatment option for this elderly population, with a durable response lasting almost one year.
A Phase Ib/II trial found that adding idh1 inhibitor ivosidenib to either venetoclax or azacitidine resulted in a high complete remission rate of 78% overall, with 100% for treatment-naïve patients. The combination may ultimately lead to a new therapeutic regimen and tailored treatment options based on molecular profiles.
A Phase II trial led by MD Anderson Cancer Center researchers found that treatment with MK-6482 resulted in a 27.9% objective response rate in patients with von Hippel-Lindau disease-associated renal cell carcinoma, with most side effects being grade 1 or 2. The drug directly targets HIF-2a and has been shown to be well-tolerated.
Researchers at MD Anderson Cancer Center and Ipsen Biopharmaceuticals have developed a novel drug, IPN60090, a glutaminase inhibitor for lung and ovarian cancers. The Phase I clinical trial shows promising results, particularly for patients with KEAP1/NRF2 mutations or low ASNS levels.
The Phase III EMBRACA trial found talazoparib improved patient-reported quality-of-life measures and had a tolerable safety profile in patients with metastatic HER2-negative breast cancer and BRCA1/2 mutations. However, the study did not demonstrate a statistically significant overall survival benefit due to subsequent treatments.
A Phase II trial found patients with metastatic castration-resistant prostate cancer who showed active T-cell responses in their tumors experienced prolonged survival after ipilimumab treatment. Researchers identified biomarkers associated with improved responses, including higher T-cell density and interferon-γ signaling.
A Phase II study found that 93% of patients with relapsed or refractory mantle cell lymphoma responded to CD19-targeting CAR T-cell therapy KTE-X19, with 67% achieving a complete response. The estimated progression-free survival and overall survival were 61% and 83%, respectively.
Researchers at MD Anderson Cancer Center propose using glucose transporter inhibitors to treat tumors with high expression of the SLC7A11 amino acid transporter. This approach targets cancer cells' dependency on glucose for survival, selectively killing 'addicted' cells.
Researchers at MD Anderson Cancer Center developed a combination therapy that reprograms effector T cells into persistent central memory T cells capable of self-renewal and effective cancer cell killing. This approach addresses the persistence challenge in cellular therapies, increasing their effectiveness.
A study found that myelin, the protective coating of nerve cells, is dynamic and not inert as traditionally believed. This discovery has implications for treatment of multiple sclerosis and chemobrain, a type of myelin damage caused by chemotherapy drugs.